Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-03-11

Clinical Trial Update: A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is recruiting to evaluate the efficacy, safety, and tolerability of remibrutinib in adults and adolescents with moderate to severe hidr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Remibrutinib (remibrutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hidradenitis Suppurativa | Phase 3 | Status: RECRUITING